Botox (onabotulinumtoxinA) manufacturer Allergan (NYSE: AGN) has accepted calls to shake up its management structure, agreeing to create a new position to stand alongside the chief executive at the time of the next leadership change.
The company gave notice of the change via its yearly proxy statement, filed with the US Securities and Exchange Commission (SEC).
Amid criticism from investors over the company’s strategy, chief executive Brent Saunders has fought off pressure to make any immediate changes to senior management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze